Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stocks in play: Oncolytics Biotech Inc Baystreet - Fri May 10, 8:35AM CDT

Announces recent operational highlights and financial results for the first quarter ended March 31, ...

ONC.TO : 1.59 (unch)
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights Newswire.ca - Thu May 9, 3:01PM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...

ONCY : 1.1798 (+0.84%)
ONC.TO : 1.59 (unch)
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 FinancialNewsMedia - Thu May 9, 11:15AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

ONCY : 1.1798 (+0.84%)
ONC.TO : 1.59 (unch)
ZLAB : 21.96 (+9.36%)
NTBL : 1.2000 (-4.00%)
CRDF : 3.50 (+3.24%)
JNJ : 150.67 (+0.51%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer FinancialNewsMedia - Thu May 9, 9:56AM CDT

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study   Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic...

ONCY : 1.1798 (+0.84%)
ONC.TO : 1.59 (unch)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Newswire.ca - Thu May 9, 9:22AM CDT

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.1798 (+0.84%)
CADL : 9.73 (+4.40%)
AZN : 77.40 (+0.29%)
HALO : 43.75 (+1.39%)
JANX : 49.09 (+0.35%)
ONC.TO : 1.59 (unch)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles BayStreet.ca - Thu May 9, 9:13AM CDT

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.1798 (+0.84%)
ONC.TO : 1.59 (unch)
CADL : 9.73 (+4.40%)
AZN : 77.40 (+0.29%)
HALO : 43.75 (+1.39%)
JANX : 49.09 (+0.35%)
Stocks in play: Oncolytics Biotech Inc. Baystreet - Thu May 9, 8:51AM CDT

Will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory ...

ONC.TO : 1.59 (unch)
Stocks in play: Oncolytics Biotech Inc Baystreet - Thu May 9, 8:14AM CDT

Received regulatory clearance to evaluate Pelareorep in combination with modified FOLFIRINOX +/- an ...

ONC.TO : 1.59 (unch)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer Newswire.ca - Thu May 9, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence...

ONCY : 1.1798 (+0.84%)
ONC.TO : 1.59 (unch)
Stocks in play: Oncolytics Biotech Inc Baystreet - Wed May 8, 8:24AM CDT

Today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside ...

ONC.TO : 1.59 (unch)

Barchart Exclusives

2 Industrial Dividend Stocks to Buy for AI-Fueled Upside Barchart - 33 minutes ago
With the surge in demand for data centers due to artificial intelligence, these two industrial companies play crucial roles in providing essential infrastructure components, making them attractive choices for investors seeking dividends and growth in this rapidly evolving sector. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot